Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ARID1B |
Variant | R1075* |
Impact List | nonsense |
Protein Effect | loss of function |
Gene Variant Descriptions | ARID1B R1075* (corresponds to R1062* in the canonical isoform) results in a premature truncation of the Arid1b protein at amino acid 1075 of 2236 (UniProt.org). R1075* results in decreased protein stability, reduced association with chromatin, and impaired cranial neural crest cell formation likely due to aberrant NANOG/SOX2 activity in patient-derived cells (PMID: 34753942). |
Associated Drug Resistance | |
Category Variants Paths |
ARID1B mutant ARID1B inact mut ARID1B R1075* |
Transcript | NM_020732.3 |
gDNA | chr6:g.157181056C>T |
cDNA | c.3223C>T |
Protein | p.R1075* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_011535988.4 | chr6:g.157207103A>T | c.3223A>T | p.R1075* | RefSeq | GRCh38/hg38 |
XM_017011105.3 | chr6:g.157150777_157150779delCGCinsTGA | c.3223_3225delCGCinsTGA | p.R1075* | RefSeq | GRCh38/hg38 |
NM_020732.3 | chr6:g.157181056C>T | c.3223C>T | p.R1075* | RefSeq | GRCh38/hg38 |
XM_011535984.3 | chr6:g.157150777_157150779delCGCinsTGA | c.3223_3225delCGCinsTGA | p.R1075* | RefSeq | GRCh38/hg38 |
XM_047419155.1 | chr6:g.157150777_157150779delCGCinsTGA | c.3223_3225delCGCinsTGA | p.R1075* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1B inact mut | melanoma | not predictive | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with melanoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 1.70 (p=0.192, n=86) and 1.02 (p=0.939, n=192), respectively (PMID: 32321774). | 32321774 |
ARID1B inact mut | transitional cell carcinoma | not predictive | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with transitional cell carcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 1.44 (p=0.34, n=56) and 0.82 (p=0.559, n=93), respectively (PMID: 32321774). | 32321774 |
ARID1B inact mut | gastroesophageal adenocarcinoma | not predictive | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with gastroesophageal adenocarcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 0.70 (p=0.403, n=66) and 0.46 (p=0.071, n=59), respectively (PMID: 32321774). | 32321774 |
ARID1B inact mut | head and neck squamous cell carcinoma | not predictive | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with head and neck squamous cell carcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 0.74 (p=0.631, n=31) and 0.76 (p=0.622, n=68), respectively (PMID: 32321774). | 32321774 |
ARID1B inact mut | colorectal adenocarcinoma | unknown | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, correlated with improved survival in one cohort of patients with colorectal adenocarcinoma treated with systemic immune checkpoint inhibitors but not the other, with adjusted HRs for overall survival of 0.30 (p=0.03, n=35) and 0.56 (p=0.244, n=63), respectively (PMID: 32321774). | 32321774 |